Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
58 Macular Degeneration Trials
Power is an online platform that helps thousands of Macular Degeneration patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Faricimab Schedules for Age-Related Macular Degeneration
Indianapolis, IndianaHome optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Dense Cataract, Pathologic Myopia, Others
Must Not Be Taking:Anti-VEGF, Corticosteroids
600 Participants Needed
Pegcetacoplan for Age-Related Macular Degeneration
Indianapolis, IndianaThis trial is testing a medication called pegcetacoplan to see if it is safe and effective for people with a severe eye condition called geographic atrophy, which is related to age-related macular degeneration. The medication aims to protect the eye by blocking harmful immune responses. Pegcetacoplan has shown an acceptable safety profile in previous studies for geographic atrophy.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60+
Sex:All
1200 Participants Needed
Axitinib Implant for Age-Related Macular Degeneration
Indianapolis, IndianaThis trial is testing a small device placed in the eye that releases medication for patients with a severe form of AMD. The medication helps stop abnormal blood vessel growth in the eye, potentially preventing further vision loss. This approach has significantly improved treatment for this condition in recent years.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
344 Participants Needed
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Indianapolis, IndianaThis trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Advanced Glaucoma, Others
Must Be Taking:Anti-VEGF
540 Participants Needed
OPT-302 + Ranibizumab for Age-Related Macular Degeneration
Indianapolis, IndianaA 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
990 Participants Needed
4D-150 + EYLEA for Age-Related Macular Degeneration
Carmel, IndianaA Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Glaucoma, Uncontrolled Blood Pressure, Others
400 Participants Needed
OCU410 for Age-Related Macular Degeneration
Carmel, IndianaThis trial tests OCU410, a gene therapy injected into the eye, for patients with severe vision loss due to advanced dry AMD. The treatment uses a virus to deliver helpful genes that may restore normal eye function.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Gene Therapy, Cell Therapy, Wet AMD, Others
63 Participants Needed
This trial is testing a new treatment called JNJ-81201887 to see if it can slow down the growth of damaged areas in the eyes of people with geographic atrophy. This condition causes parts of the retina to deteriorate, and the treatment aims to protect the retina and preserve vision.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60+
Sex:All
305 Participants Needed
OCU-10-C-110 Injection for Age-Related Macular Degeneration
Carmel, IndianaMulti-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Cancer, Dementia, Others
Must Be Taking:Anti-VEGF
19 Participants Needed
EYP-1901 vs Aflibercept for Age-Related Macular Degeneration
Carmel, IndianaThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Subfoveal Fibrosis, Atrophy, Scarring, Others
Must Be Taking:Anti-VEGF Injections
400 Participants Needed
Elamipretide for Age-Related Macular Degeneration
Carmel, IndianaThe goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:55+
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetic Retinopathy, Organ Transplant, Cancer, Others
Must Not Be Taking:Plaquenil, Tamoxifen, Digoxin, Others
360 Participants Needed
RGX-314 Gene Therapy for Age-Related Macular Degeneration
Carmel, IndianaThis trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Advanced Glaucoma, Others
Must Be Taking:Anti-VEGF
660 Participants Needed
AVD-104 for Age-Related Macular Degeneration
Indianapolis, IndianaInvestigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 90
Sex:All
300 Participants Needed
4D-150 for Age-Related Macular Degeneration
Carmel, IndianaPhase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uveitis, Photodynamic Therapy, Others
Must Be Taking:Anti-VEGF
215 Participants Needed
Iptacopan for Age-Related Macular Degeneration
Indianapolis, IndianaThis trial tests if Iptacopan capsules can prevent worsening of early or intermediate AMD in people who already have severe AMD in one eye. The goal is to see if the medication can protect eye cells and slow down vision loss.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac Arrhythmias, Stroke, Myocardial Infarction, End Stage Kidney Disease, Malignancy, Others
146 Participants Needed
CG-P5 Peptide for Age-Related Macular Degeneration
Carmel, IndianaThis will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Glaucoma, Others
Must Not Be Taking:Retina-toxic Drugs
45 Participants Needed
D-4517.2 for Age-Related Macular Degeneration and Diabetic Macular Edema
Indianapolis, IndianaThis trial tests a new injectable drug, D-4517.2, in people with wet AMD or DME. The drug aims to block a protein that causes harmful blood vessel growth in the eye, potentially preventing further vision loss.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
50 Participants Needed
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Monocular, Fibrosis, Atrophy, Others
675 Participants Needed
Foselutoclax for Diabetic Macular Edema
Carmel, IndianaThis trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
52 Participants Needed
OPT-302 + Aflibercept for Age-Related Macular Degeneration
New Albany, IndianaA 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
990 Participants Needed
BI 771716 for Age-Related Macular Degeneration
Louisville, KentuckyThis study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.
In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye.
Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Exudative AMD, Uncontrolled Glaucoma, Others
180 Participants Needed
Danicopan for Age-Related Macular Degeneration
Cincinnati, OhioThis trial is testing a medication called danicopan to see if it can help people with a specific type of eye disease called Geographic Atrophy, which is related to Age-related Macular Degeneration. The study will check how well the medication works, how safe it is, and how the body handles it.
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60+
Sex:All
365 Participants Needed
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications.
The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Proliferative Diabetic Retinopathy, Others
Must Be Taking:Anti-VEGF
1118 Participants Needed
NG101 Gene Therapy for Age-Related Macular Degeneration
Cincinnati, OhioThis study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Glaucoma, Retinal Detachment, Others
Must Be Taking:Anti-VEGF Injections
18 Participants Needed
JNJ-81201887 for Age-Related Macular Degeneration
Cincinnati, OhioThe purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:60+
Sex:All
311 Participants Needed
HLX04-O vs Ranibizumab for Wet Age-Related Macular Degeneration
Louisville, KentuckyThis study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
388 Participants Needed
SUSVIMO for Age-Related Macular Degeneration
Blue Ash, OhioThis study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Glaucoma, Autoimmune Diseases, Cancer, Others
Must Be Taking:Anti-VEGF
188 Participants Needed
OpRegen for Age-Related Macular Degeneration
Cincinnati, OhioThis trial is testing OpRegen, a cell injection treatment, in patients with severe vision loss due to age-related macular degeneration. The goal is to see if injecting these cells under the retina can help repair or support damaged eye cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Dementia, Systemic Disease, Others
60 Participants Needed
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Ocular Diseases, Uncontrolled Hypertension, Others
Must Be Taking:Anti-VEGF Injections
1000 Participants Needed
OpRegen for Age-Related Macular Degeneration
Cincinnati, OhioThis trial is testing a new treatment using special cells from human embryos to help people with a type of vision loss called dry-AMD. The treatment involves injecting these cells into the eye to see if they can survive and slow down the disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
24 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Macular Degeneration clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Macular Degeneration clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Macular Degeneration trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Macular Degeneration is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Macular Degeneration medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Macular Degeneration clinical trials ?
Most recently, we added MB-102 Dye for Retinal Disorders, Faricimab for Age-Related Macular Degeneration and 4D-150 + EYLEA for Age-Related Macular Degeneration to the Power online platform.